The L-Malic Acid test kit is suitable for the measurement and analysis of L-malic acid in grapes, grape juice and wine using the MegaQuant™ colorimeter (measurement at 505 nm). Suitable for white and red wines at all stages of the winemaking process.
Detail
K-LMALMQ
60 assays per kit
Content:
60 assays per kit
Shipping Temperature:
Ambient
Storage Temperature:
Short term stability: 2-8oC, Long term stability: See individual component labels
Stability:
> 2 years under recommended storage conditions
Analyte:
L-Malic Acid
Assay Format:
Spectrophotometer
Detection Method:
Absorbance
Wavelength (nm):
505
Signal Response:
Increase
Linear Range:
0.15 to 15 µg of L-malic acid per assay (i.e. 0.007-0.75 g/L with a 20 µL sample volume)
Limit of Detection:
15.4 mg/L
Reaction Time (min):
~ 6 min
Application examples:
Wine, beer, fruit juices, soft drinks, candies, fruit and vegetables, bread, cosmetics, pharmaceuticals and other materials (e.g. biological cultures, samples, etc.).
The L-Malic Acid test kit is suitable for the measurement and analysis of L-malic acid in grapes, grape juice and wine using the MegaQuant™ colorimeter (measurement at 505 nm). Suitable for white and red wines at all stages of the winemaking process.
Our SNPsig® kits use our own proprietary genotyping method to enable the identification of SARS-CoV-2 variants of concern. These products can be used on any real-time PCR machine using familiar protocols, whilst resulting in exceptional genotyping data.
Positive control templates for wild-type and variants are supplied in every kit to make data interpretation simple.
Our SNPsig® technology provides an alternative to sequencing as well as S gene target failure (SGTF) that enables scientists to analyse and monitor these specific genomic mutations. Our kits can provide a pivotal role in screening for SARS-CoV-2 variants for the purpose of genomic surveillance and studies.
Document
For the detection of the SARS-CoV-2 (20J/501Y.V3 Brazil) Rapid detection of specific detection profiles High priming efficiency Sensitive to < 100 copies of target
Positive copy number standard curve for quantification
Accurate controls to confirm findings
96 reactions, includes master mix
N-(Propargyl-PEG4)-N-bis(PEG4-acid) is a branched crosslinking reagent with a propargyl group and two terminal carboxylic acids. The propargyl group can react with azide-bearing compounds or biomolecules via copper catalyzed azide-alkyne Click Chemistry to yield a stable triazole linkage. The terminal carboxylic acids can react with primary amino groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
Document
N-(Propargyl-PEG4)-N-bis(PEG4-acid) is a branched crosslinking reagent with a propargyl group and two terminal carboxylic acids. The propargyl group can react with azide-bearing compounds or biomolecules via copper catalyzed azide-alkyne Click Chemistry to yield a stable triazole linkage. The terminal carboxylic acids can react with primary amino groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
The cfDNA Purification Kit (Magnetic Beads) was developed for cell free DNA (cfDNA) enrichment by separating genomic DNA contamination from isolated cfDNA samples.
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
Therefore, an additional purification step to enrich cfDNA before downstream methods helps to improve signal from fragments that originate from cancer cells. A proportion of cancer-derived cfDNA fragment signals are below 100 bp and are often not detectable except by qPCR or single-stranded DNA based library preparation for NGS (1, 2, 3). Furthermore only 1% of cancer-derived fragments are found above 400 bp (1, 2). Capture of size-selected fragments between 90-150 bp improved detection of cancer by 2-4 fold (4). Furthermore, TF-bound and protected cfDNA fragments are also being investigated for active cancer-specific signals down to 35-80 bp (5, 6).
This kit uses Dual Solid Phase Reversible Immobilization (SPRI) technology for cfDNA purification. Most Dual SPRI procedures do NOT recover fragments below 100 bp. The kit can be used for the enrichment of cfDNA isolated from liquid biopsies, plasma, serum, and urine. The kit separates cfDNA (50-500 bp) and genomic DNA, and recovers of 90% of the cfDNA without the high molecular weight genomic DNA with high efficiency. Fragments at 500 bp and above may also be retained. Both the 50-500 bp and >500 bp DNA fractions can be used for downstream applications such as single-stranded or double stranded NGS library prep, qPCR, ddPCR, and other methods.
Features
Separation of cfDNA and genomic DNA; Recovery of both types of DNA
Recovery of cfDNA (50-500 bp)
As short as 50 bp can be recovered
Recovery of high molecular weight genomic DNA
Removal of unwanted components and other impurities
Automation friendly
Examples of cfDNA purification. Both cfDNA and genomic DNA can be recovered separately.
The range of recovered small DNA fragments is from 50 to 500 bp. The input DNA are mixtures of sheared small DNA fragments and intact genomic DNA. The ratios of sheared DNA fragments versus genomic DNA are indicated.
Recovery rates of cfDNA and genomic DNA.
Document
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
